RJA
ANIX icon

Raymond James & Associates’s Anixa Biosciences ANIX Stock Holding History

Raymond James & Associates’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$49.6K Sell
15,752
-2,003
-11% -$6.16K ﹤0.01% 3855
2024
Q2 		$39.2K Hold
17,755
– – ﹤0.01% 3820
2024
Q1 		$55.4K Sell
17,755
-37,894
-68% -$151K ﹤0.01% 3793
2023
Q4 		$216K Sell
55,649
-933
-2% -$3.15K ﹤0.01% 3478
2023
Q3 		$185K Buy
56,582
+100
+0.2% +$350 ﹤0.01% 3484
2023
Q2 		$181K Sell
56,482
-467
-0.8% -$1.8K ﹤0.01% 3502
2023
Q1 		$245K Sell
56,949
-268
-0.5% -$1.17K ﹤0.01% 3381
2022
Q4 		$243K Sell
57,217
-3,629
-6% -$17.5K ﹤0.01% 3337
2022
Q3 		$299K Sell
60,846
-4,672
-7% -$18.9K ﹤0.01% 3181
2022
Q2 		$200K Sell
65,518
-50
-0.1% -$158 ﹤0.01% 3506
2022
Q1 		$180K Buy
65,568
+8,666
+15% +$25.4K ﹤0.01% 3699
2021
Q4 		$169K Buy
56,902
+5,352
+10% +$21.6K ﹤0.01% 3754
2021
Q3 		$246K Sell
51,550
-2,506
-5% -$11.3K ﹤0.01% 3552
2021
Q2 		$210K Buy
54,056
+11,726
+28% +$49.9K ﹤0.01% 3655
2021
Q1 		$198K Buy
+42,330
New +$202K ﹤0.01% 3614
2020
Q2 		– Sell
-10,040
Closed -$16K – 3519
2020
Q1 		$16K Hold
10,040
– – ﹤0.01% 3417
2019
Q4 		$33K Hold
10,040
– – ﹤0.01% 3580
2019
Q3 		$40K Hold
10,040
– – ﹤0.01% 3489
2019
Q2 		$36K Buy
+10,040
New +$42.4K ﹤0.01% 3527

Other funds holding ANIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MWM
Mission Wealth Management Santa Barbara, California $4.86B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's ANIX Position: Q3 2024 in Review

Raymond James & Associates reduced its Anixa Biosciences (ANIX) stake by 11% in Q3 2024, selling an estimated $6.16K and leaving 15,752 shares worth $49.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3855.

Raymond James & Associates first reported a position in ANIX in Q2 2019 and has held it in 19 quarters since. The position peaked at $299K in Q3 2022. 58 funds tracked by Wall St. Rank hold ANIX as of Q3 2024.

  • Raymond James & Associates held 15,752 shares of Anixa Biosciences worth $49.6K as of Q3 2024.
  • Raymond James & Associates sold 2,003 Anixa Biosciences shares in Q3 2024, an estimated $6.16K.
  • Anixa Biosciences made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3855 holding.
  • Raymond James & Associates first reported a position in Anixa Biosciences in Q2 2019 and has held it in 19 quarters since.
  • Raymond James & Associates's Anixa Biosciences position peaked at $299K in Q3 2022.
  • 58 funds tracked by Wall St. Rank held Anixa Biosciences as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.